2018
Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis
Hendricks W, Zismann V, Sivaprakasam K, Legendre C, Poorman K, Tembe W, Perdigones N, Kiefer J, Liang W, DeLuca V, Stark M, Ruhe A, Froman R, Duesbery N, Washington M, Aldrich J, Neff M, Huentelman M, Hayward N, Brown K, Thamm D, Post G, Khanna C, Davis B, Breen M, Sekulic A, Trent J. Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis. PLOS Genetics 2018, 14: e1007589. PMID: 30188888, PMCID: PMC6126841, DOI: 10.1371/journal.pgen.1007589.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCell CycleCell ProliferationComparative Genomic HybridizationDNA Mutational AnalysisDog DiseasesDogsFemaleMaleMelanomaMutationProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)Receptor-Like Protein Tyrosine Phosphatases, Class 3Signal TransductionSkin NeoplasmsTissue Array AnalysisConceptsLow point mutation ratePowerful comparative modelComparative genomic analysisCell cycle controlPoint mutation rateSingle nucleotide polymorphism arrayNucleotide polymorphism arrayWhole-genome sequencingArray comparative genomic hybridizationHuman melanomaComparative genomic hybridizationGenomic analysisRNA sequencingCycle controlGenome sequencingMutation rateGenomic landscapePolymorphism arrayCopy numberMutational landscapeMutational signaturesGenomic hybridizationRecurrent alterationsMulti-platform analysisMutations
2017
KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells
London CA, Gardner HL, Rippy S, Post G, La Perle K, Crew L, Lopresti-Morrow L, Garton AJ, McMahon G, LaVallee TM, Gedrich R. KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells. Clinical Cancer Research 2017, 23: 2565-2574. PMID: 27815356, PMCID: PMC5418113, DOI: 10.1158/1078-0432.ccr-16-2152.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntibodies, MonoclonalCell ProliferationDog DiseasesDogsFemaleHumansMast CellsMutationPhosphorylationProto-Oncogene Proteins c-kitConceptsMast cell tumorsSpontaneous mast cell tumoursMast cell numbersMast cell degranulationCutaneous mast cell numberKIT phosphorylationCell degranulationOpen-label clinical studyBiochemical adverse eventsAcceptable safety profileMetastatic lymph nodesPharmacokinetics/pharmacodynamics profileFuture clinical evaluationClin Cancer ResCell numberDose-dependent mannerObjective responseAdverse eventsLymph nodesMCT patientsClinical effectsClinical toxicityClinical benefitHuman clinical applicationsSafety profile